S&P Equity Research downgrades Bristol-Myers Squibb (NYSE: BMY) from Hold to Sell. Price target lowered from $27 to $17 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE